---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-031383"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-22T00:00:16.751178+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Indaptus Q3 2022: cash $28.5M, loss $0.42/share; Decoy20 Phase 1 to start Q4 2022

## Summary
- Cash, equivalents and marketable securities of $28.5M as of Sep 30, 2022, down from $39.1M at Dec 31, 2021.
- R&D expenses of $1.6M in Q3 2022, up $900K vs Q3 2021, driven by Phase 1 trial preparation and manufacturing costs.
- G&A expenses of $2.0M in Q3 2022, down $700K vs Q3 2021, due to lower merger-related costs.
- Loss per share of $0.42 in Q3 2022 vs $0.81 in Q3 2021; net loss of $2.3M for the quarter.
- Phase 1 trial of Decoy20 for solid tumors remains on track to initiate in Q4 2022 after FDA IND clearance in May.

## SEC filing metadata
- accession: 0001493152-22-031383
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315222031383/0001493152-22-031383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315222031383/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-031383
- JSON: https://secwatch.observer/filing/0001493152-22-031383.json
- Plain text: https://secwatch.observer/filing/0001493152-22-031383.txt

## Key facts
- Earnings Releases
  Indaptus Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 10, 2022, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s results of operations for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315222031383/0001493152-22-031383-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.